专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20080160067A1 Novel soft chewable, tablet, and long-acting injectable veterinary antibiotic formulations 审中-公开
标题翻译：新型软咀嚼片，片剂和长效注射用兽药抗生素配方
公开(公告)号：US20080160067A1
公开(公告)日：2008-07-03
申请号：US11899282
申请日：2007-09-05
申请人： Albert Boeckh , Mark D. Soll , Monica Tejwani-Motwani , Robert P. Waranis , Fangjun Wu
发明人： Albert Boeckh , Mark D. Soll , Monica Tejwani-Motwani , Robert P. Waranis , Fangjun Wu
IPC分类号： A61K9/68 , A61K31/40
CPC分类号： A61K9/0056 , A61K9/0019 , A61K9/2013 , A61K9/2018 , A61K47/10
摘要： This document relates to formulations for combating bacterial infections in animals which provide for improved long-acting oral and injectable formulations for systemic delivery of antibiotics, which are designed to achieve high bioavailability.
摘要翻译：本文件涉及用于对抗动物细菌感染的制剂，其提供改进的用于系统递送抗生素的长效口服和可注射制剂，其被设计为实现高生物利用度。

2. 发明授权

US06991801B2 Topical anthelmintic veterinary formulations 有权
标题翻译：主题驱虫剂兽药配方
公开(公告)号：US06991801B2
公开(公告)日：2006-01-31
申请号：US10818313
申请日：2004-04-05
申请人： Mark D. Soll , Krishan Kumar , Robert P. Waranis , Natalya Shub
发明人： Mark D. Soll , Krishan Kumar , Robert P. Waranis , Natalya Shub
IPC分类号： A01N25/32
CPC分类号： A61K9/0017 , A61K31/365 , A61K31/495 , A61K31/506 , A61K2300/00
摘要： This invention provides for inter alia, topical anthelmintic formulations which comprise a pharmaceutically active combination consisting of at least one macrocyclic compound and at least one compound selected from the group consisting of praziquantel, morantel and pyrantel, which are dissolved in a non-aqueous solvent or solvent mixture and optionally a thickening agent.
摘要翻译：本发明尤其提供了包含由至少一种大环化合物和至少一种选自吡喹酮，芒硝和吡哆醇的化合物组成的药物活性组合的局部驱肠制剂，它们溶于非水溶剂或溶剂混合物和任选的增稠剂。

3. 发明授权

US06745546B2 Encapsulation machine with valved injection wedge 失效
标题翻译：带有注射楔的封装机
公开(公告)号：US06745546B2
公开(公告)日：2004-06-08
申请号：US10015974
申请日：2001-11-02
申请人： Keith Tanner , Robert P. Waranis
发明人： Keith Tanner , Robert P. Waranis
IPC分类号： B65B4700
CPC分类号： A61J3/07 , A61J2200/20 , A61J2200/42 , B29C47/0021 , B29C47/14 , B29C47/56
摘要： This invention relates to a method and apparatus for forming soft capsules and provides novel processing flexibility. The apparatus comprises a three-way valve injector wedge. This injector wedge allows for set-up of the encapsulation machine with a placebo fill and quick change over to active fill. This conserves use of the active ingredient.
摘要翻译：本发明涉及一种形成软胶囊的方法和装置，并且提供了新的加工灵活性。该装置包括三通阀注射器楔。该注射器楔子允许用安慰剂填充装置安装封装机，并快速切换到主动填充。这节省了活性成分的使用。

4. 发明授权

US5516770A Rapamycin formulation for IV injection 失效
标题翻译：雷帕霉素配方用于IV注射
公开(公告)号：US5516770A
公开(公告)日：1996-05-14
申请号：US308923
申请日：1994-09-22
申请人： Robert P. Waranis , Thomas W. Leonard
发明人： Robert P. Waranis , Thomas W. Leonard
IPC分类号： A61K9/08 , A61K9/00 , A61K31/435 , A61K47/10 , A61K47/26 , A61K31/33
CPC分类号： A61K47/26 , A61K31/435 , A61K47/10 , A61K9/0019
摘要： Disclosed herein is an aqueous, injectable rapamycin solution, obtained by a process consisting of mixing 5 to 30 volume percent of a concentrate solution of rapamycin in propylene glycol, at concentrations of rapamycin ranging from 0.5 mg/ml to 10 mg/ml, with a diluent solution consisting of 0.1 to 10 weight percent of one or more polyoxyethylene sorbitan esters, 10 to 60 weight percent of polyethylene glycol 200, 300 or 400 or a combination thereof and 30 to 89.9 volume percent water, wherein the concentration of rapamycin in the injectable solution ranges from 0.025 mg/ml to 3 mg/ml.
摘要翻译：本文公开了一种水性可注射的雷帕霉素溶液，其通过以5至30体积％的雷帕霉素在丙二醇中的浓缩液混合，浓度为0.5mg / ml至10mg / ml的雷帕霉素的方法获得，稀释溶液由0.1至10重量％的一种或多种聚氧乙烯脱水山梨糖醇酯，10至60重量％的聚乙二醇200,300或400或其组合和30至89.9体积％的水组成，其中雷帕霉素在可注射的溶液的范围为0.025mg / ml至3mg / ml。

5. 发明授权

US06990791B2 Encapsulation machine with valved injection wedge 失效
公开(公告)号：US06990791B2
公开(公告)日：2006-01-31
申请号：US10821538
申请日：2004-04-09
申请人： Keith Tanner , Robert P. Waranis
发明人： Keith Tanner , Robert P. Waranis
IPC分类号： B65B47/00 , B29C47/14
CPC分类号： A61J3/07 , A61J2200/20 , A61J2200/42 , B29C47/0021 , B29C47/14 , B29C47/56
摘要： This invention relates to a method and apparatus for forming soft capsules and provides novel processing flexibility. The apparatus comprises a three-way valve injector wedge. This injector wedge allows for set-up of the encapsulation machine with a placebo fill and quick change over to active fill. This conserves use of the active ingredient.

6. 发明授权

US5530006A Rapamycin formulation for IV injection 失效
标题翻译：雷帕霉素配方用于IV注射
公开(公告)号：US5530006A
公开(公告)日：1996-06-25
申请号：US207325
申请日：1994-03-07
申请人： Robert P. Waranis , Maureen M. Harrison , Thomas W. Leonard , Robin P. Enever
发明人： Robert P. Waranis , Maureen M. Harrison , Thomas W. Leonard , Robin P. Enever
IPC分类号： A61K31/70 , A61K47/10 , A61K47/18 , A61K47/26 , A61P37/06 , A61K31/44
CPC分类号： A61K31/70 , A61K47/10 , A61K47/18 , A61K47/26 , A61K9/0019
摘要： Disclosed herein is an aqueous, injectable rapamycin solution comprising 0.1 to 10 percent of a concentrate solution of rapamycin in N,N-dimethylacetamide, at concentrations of rapamycin ranging from 0.25 mg/ml to 100 mg/ml, in combination with a diluent solution consisting of 0.1 to 10 weight percent of one or more polyoxyethylene sorbitan esters, 10 to 60 weight percent of either polyethylene glycol 200 or 300 or both and 30 to 90 volume percent water, wherein the concentration of rapamycin in he combined solution ranges from 0.05 mg/ml to 5.0 mg/ml. Also disclosed is an aqueous, injectable solution of rapamycin, said solution comprising rapamycin in 0.1 to 10 weight percent N,N-dimethylacetamide, 0.09 to 7.5 weight percent of one or more polyoxyethylene sorbitan esters, 9 to 60 weight percent of either polyethylene glycol 200 or 300 or both and 30 to 90 volume percent of water, wherein the concentration of rapamycin in the solution ranges from 0.05 mg/ml to 5.0 mg/ml. Preferred aqueous, injectable rapamycin solutions are those wherein one polyoxyethylene sorbitan ester is present and the polyethylene glycol present is polyethylene glycol 300.
摘要翻译：本文公开了一种含水可注射的雷帕霉素溶液，其包含雷帕霉素在N，N-二甲基乙酰胺中的浓度为0.1至10％的浓度的雷帕霉素浓度为0.25mg / ml至100mg / ml的浓度溶液， 0.1至10重量％的一种或多种聚氧乙烯脱水山梨糖醇酯，10至60重量％的聚乙二醇200或300或两者和30至90体积％的水，其中雷帕霉素在其组合溶液中的浓度范围为0.05mg / ml至5.0mg / ml。还公开了雷帕霉素的水性注射溶液，所述溶液包含0.1至10重量％的N，N-二甲基乙酰胺，0.09至7.5重量％的一种或多种聚氧乙烯脱水山梨醇酯，9至60重量％的聚乙二醇200 或300或以上或30至90体积％的水，其中所述溶液中雷帕霉素的浓度为0.05mg / ml至5.0mg / ml。优选的水性可注射雷帕霉素溶液是其中存在一种聚氧乙烯脱水山梨糖醇酯并且存在的聚乙二醇是聚乙二醇300的溶液。

7. 发明授权

US5616588A Rapamycin formulation for IV injection 失效
标题翻译：雷帕霉素配方用于IV注射
公开(公告)号：US5616588A
公开(公告)日：1997-04-01
申请号：US302190
申请日：1994-09-12
申请人： Robert P. Waranis , Thomas W. Leonard
发明人： Robert P. Waranis , Thomas W. Leonard
IPC分类号： A61K9/00 , A61K31/435 , A61K47/10 , A61K31/44
CPC分类号： A61K31/435 , A61K47/10 , A61K9/0019
摘要： Disclosed herein is an aqueous, injectable rapamycin solution comprising 40 to 75 volume percent of a concentrate solution of rapamycin in propylene glycol, at concentrations of rapamycin ranging from 0.25 mg/ml to 8 mg/ml, in combination with a diluent solution comprising water, wherein the diluent comprises 60 to 25 volume percent of the combined solution and the concentration of rapamycin in the combined solution ranges from 0.1 mg/ml to 4 mg/ml.
摘要翻译：本文公开了一种水性可注射雷帕霉素溶液，其包含40至75体积％的雷帕霉素在丙二醇中的浓缩物浓度为0.25mg / ml至8mg / ml的雷帕霉素浓缩液，与包含水的稀释剂溶液组合，其中稀释剂包含60至25体积％的组合溶液，并且组合溶液中雷帕霉素的浓度范围为0.1mg / ml至4mg / ml。

8. 发明授权

US5559121A Rapamycin formulations for oral administration 失效
标题翻译：用于口服给药的雷帕霉素制剂
公开(公告)号：US5559121A
公开(公告)日：1996-09-24
申请号：US448280
申请日：1995-05-23
申请人： Maureen M. Harrison , Christian L. Ofslager , Robert P. Waranis , Thomas W. Leonard
发明人： Maureen M. Harrison , Christian L. Ofslager , Robert P. Waranis , Thomas W. Leonard
IPC分类号： A61K9/08 , A61K9/127 , A61K9/48 , A61K31/435 , A61K31/436 , A61K31/70 , A61K47/00 , A61K47/10 , A61K47/18 , A61K47/24 , A61K47/26 , A61P31/04 , A61P35/00 , A61P37/06 , A61K31/33 , A61K31/71
CPC分类号： A61K47/24 , A61K31/435 , A61K47/18 , A61K9/4858 , A61K47/10 , A61K47/26 , A61K9/1277
摘要： The present invention comprises oral rapamycin formulations which contain, per 100 ml of the formulation, from about 0.01 to about 10.0 grams per 100 ml of rapamycin, from about 0.1 to about 10 ml of surfactant, from about 0.1 to about 25 ml of N,N-dimethylacetamide, and from about 65 to about 99.8 ml of a lecithin or phospholipid solution.
摘要翻译：本发明包括口服雷帕霉素制剂，其每100ml制剂含有约0.01至约10.0克/ 100ml雷帕霉素，约0.1至约10ml表面活性剂，约0.1至约25ml的N， N-二甲基乙酰胺和约65至约99.8ml卵磷脂或磷脂溶液。

9. 发明授权

US5536729A Rapamycin formulations for oral administration 失效
标题翻译：用于口服给药的雷帕霉素制剂
公开(公告)号：US5536729A
公开(公告)日：1996-07-16
申请号：US301179
申请日：1994-09-09
申请人： Robert P. Waranis , Thomas W. Leonard
发明人： Robert P. Waranis , Thomas W. Leonard
IPC分类号： A61K9/08 , A61K20060101 , A61K9/127 , A61K9/48 , A61K31/33 , A61K31/365 , A61K31/435 , A61K31/445 , A61K31/70 , A61K35/74 , A61K47/00 , A61K47/10 , A61K47/18 , A61K47/24 , A61K47/26 , A61P31/02 , A61P31/10 , A61P35/00 , A61P37/00 , A61P37/06 , C07D498/12
CPC分类号： A61K9/4858 , A61K31/435 , A61K47/18 , A61K47/24 , A61K47/10 , A61K47/26 , A61K9/1277
摘要： The present invention provides novel oral rapamycin formulations which have, per 100 ml of the formulation, from about 0.01 grams to about 5.0 grams of rapamycin, from about 0.05% to about 10% by volume of surfactant, and from about 75% to about 99.95% by volume of a solution of phospholipid or lecithin in which the phospholipid or lecithin therein is 40% to 75% by weight.
摘要翻译：本发明提供新的口服雷帕霉素制剂，其每100ml制剂具有约0.01克至约5.0克雷帕霉素，约0.05％至约10体积％的表面活性剂和约75％至约99.95 磷脂或卵磷脂溶液的体积比例为其中磷脂或卵磷脂的重量百分比为40％至75％。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式